Early Parkinson's Disease Monotherapy With CVN424

PHASE2CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

September 11, 2023

Primary Completion Date

January 30, 2025

Study Completion Date

February 13, 2025

Conditions
Parkinson's Disease
Interventions
DRUG

CVN424 150 mg

Participants will receive 1 CVN424 tablet (150 mg) per day.

DRUG

Placebo

Participants will receive 1 matching placebo tablet per day.

Trial Locations (42)

10021

Weill Cornell Medicine, New York

10029

Icahn School of Medicine at Mount Sinai, New York

11725

Parkinson's Research Centers of America - Long Island, Commack

12208

Albany Medical Center, Albany

22031

Inova Neurology - Fairfax, Fairfax

22042

Inova Fairfax Medical Campus, Falls Church

27705

Duke University Medical Center, Durham

30912

Augusta University, Augusta

32825

N1 Research LLC, Orlando

33486

Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton

33487

SFM Clinical Research, LLC, Boca Raton

33613

University of South Florida Parkinson's Disease and Movement Disorders Center, Tampa

33980

Parkinson's Disease Treatment Center of SWFL, Port Charlotte

35233

University of Alabama at Birmingham, Birmingham

38157

Veracity Neuroscience, Memphis

40536

University of Kentucky, Center for Clinical and Translational Sciences, Lexington

43210

The Ohio State University Department of Neurology - Madden Center for Parkinson Disease and Other Movement Disorders, Columbus

The Ohio State University Wexner Medical Center, Columbus

43221

Martha Morehouse Medical Plaza, Columbus

45212

Riverhills Healthcare, Inc dba Riverhills Neuroscience, Cincinnati

48109

University of Michigan Department of Neurology, Ann Arbor

48334

Quest Research Institute, Farmington Hills

53226

Froedtert Hospital Department of Neurology, Milwaukee

Medical College of Wisconsin Department of Neurology, Milwaukee

55427

Struthers Parkinson's Center, Golden Valley

66160

University of Kansas Medical Center, Kansas City

77065

Gill Neuroscience, Houston

77429

Horizon Clinical Research Group, Cypress

78628

Texas Movement Disorder Specialists, PLLC, Georgetown

78681

Central Texas Neurology Consultants, Round Rock

80113

CenExel Rocky Mountain Clinical Research, Englewood

85013

Barrow Neurological Institute, Phoenix

St Joseph's Hospital and Medical Center, Phoenix

85258

Movement Disorders Center of Arizona, LLC, Scottsdale

85326

Muhammad Ali Parkinson Center, Phoenix

94301

Parkinson's Research Centers of America - Palo Alto, Palo Alto

97239

Oregon Health & Science University, Portland

98034

EvergreenHealth Neuroscience Institute, Kirkland

EvergreenHealth Research Department, Kirkland

40536-0284

University of Kentucky, Dept of Neurology Kentucky Neuroscience Institute Research, Lexington

02215

Beth Israel Deaconess Medical Center, Boston

48109-5872

University of Michigan Hospital / Michigan Clinical Research Unit (MCRU) Cardiovascular Center, Ann Arbor

All Listed Sponsors
lead

Cerevance Beta, Inc.

INDUSTRY

NCT06006247 - Early Parkinson's Disease Monotherapy With CVN424 | Biotech Hunter | Biotech Hunter